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Abstract | Although the development of mitochondrial therapies has largely focused on 
diseases caused by mutations in mitochondrial DNA or in nuclear genes encoding 
mitochondrial proteins, it has emerged that mitochondrial dysfunction also contributes to the 
pathology of many common disorders, including neurodegeneration, metabolic disease, heart 
failure, ischaemia-reperfusion injury and protozoal infections. Mitochondria therefore 
represent an important drug target for these highly prevalent diseases.  Several strategies 
aimed at therapeutically restoring mitochondrial function are emerging and a small number of 
agents have entered clinical trials. This review will discuss the opportunities and challenges 
faced for the further development of a mitochondrial pharmacology for common pathologies. 
 
 
 
 
Introduction  
Mitochondria perform many key roles in the cell, most notably oxidative phosphorylation, 
central carbon metabolism and the biosynthesis of intermediates for cell growth, but they are 
also responsible for several other essential processes that determine cell function and fate 1,2 
3-6 7  (FIG. 1 and Box 1). Consequently, mutations in nuclear or mtDNA genes that disrupt 
mitochondrial function lead to devastating “primary” mitochondrial diseases 3,8-10 1,11. Our 
knowledge of how mitochondria function in the cell has expanded dramatically. It is now 
clear that mitochondria participate in nearly all aspects of cell function, affecting processes 
not traditionally linked with the organelle, including cancer, inflammation, metabolic 
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signalling, and cell death, transformation and fate 5,6 7. Consequently, mitochondrial 
dysfunction has been found to contribute to many common disorders, including 
neurodegeneration, metabolic disease and heart failure 4,5,12,13. These “secondary” 
mitochondrial diseases can arise even if the proximal cause is not mitochondrial, for example 
when the initiating disease process disrupts mitochondrial function as a downstream effect 
6,10,12,14-16 7. Thus, drugs designed to act on mitochondria may be effective therapies for a 
range of common diseases, and could be more effective than when applied to the notoriously 
hard to treat diseases that arise due to mutations in mitochondrial genes 3,12 14 7 10. 
Importantly, drugs designed to affect mitochondrial function can be applied to many highly 
prevalent diseases and pathological processes, with important social, medical and economic 
impacts 2,17,18. In many cases progress in developing new therapeutic approaches for these 
common diseases has been dispiritingly slow, as is illustrated by the lack of new drugs 
coming to market for stroke or neurodegenerative diseases.  Focusing on mitochondria offers 
a promising alternative approach to developing new therapeutic options for these disorders 
14,19,20. Examples of mitochondrial agents that are currently being, or  have recently been,  
assessed in humans include agents to replenish NAD+ pools such as nicotinamide 
mononucleotide  (NMN) 21,  mitochondria-targeted protective compounds such as MitoQ 22,23  
and Bendavia  24, antioxidants such  as Coenzyme Q10 25 and  Cyclosporin A, an inhibitor of 
the mitochondrial permeability transition pore 26 27.  Given that the development and 
application of drugs designed to affect mitochondria is still in its infancy, this review will 
focus on the general principles, vast potential and ongoing challenges for intervening at the 
mitochondrial level.    
 
Rationale for targeting mitochondria  
 
Disruption to mitochondrial bioenergetic and metabolic function can lead to many secondary 
mitochondrial disorders (FIG. 1). Interestingly, common patterns regarding how 
mitochondria contribute to the aetiology of disparate pathologies have emerged 5,14,28. 
Important among these are: the aberrant production of reactive oxygen species (ROS), 
calcium dyshomeostasis, defective mitochondrial biogenesis, disruption to mitochondrial 
dynamics and quality control, necrotic cell death through induction of the permeability 
transition pore (MPTP), inappropriate activation or suppression of apoptosis, lowered cellular 
ATP/ADP ratio, decreased NAD+ levels and alterations to mitochondrial signaling pathways 
(FIG. 1) 14,28,29 7 . In many cases these different types of organelle dysfunction are linked 
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mechanistically, hence are often found together, and in addition they may contribute to 
disease by acute, irreversible cell death, long term disruption to the role of mitochondria as 
signaling hubs, or to the life-long accumulation of environmental damage that leads to a 
degenerative disorder 15. The details of how mitochondrial dysfunction leads to specific 
pathologies are discussed below.  
 In short, there are three factors supporting the pursuit of mitochondria as a therapeutic 
target for common pathologies. First, many prevalent diseases are “secondary” mitochondrial 
disorders in that mitochondrial dysfunction contributes to the disease process or clinical 
progression. Hence, targeting the organelle can improve patient outcome, even though 
mitochondrial dysfunction may not be the primary driver of pathology. Second, mitochondria 
contribute to diverse pathologies through common pathways 10,14, therefore a single 
therapeutic approach may apply to multiple disorders. Finally, the common diseases where 
targeting mitochondria show promise are of increasing medical, social and economic impact 
in our aging population. Given that the development of new drugs for these disorders has 
been frustratingly slow, new approaches are needed 30 31 32.  
 
Therapeutic approaches to mitochondria  
There are a number of approaches aimed at modulating mitochondrial function in primary 
and secondary mitochondrial diseases 3,9. These include:  behavioural interventions, such as 
changes in diet or exercise 33; exposure to hypoxia 34; stem cell therapies 35; replacing 
defective mtDNA in an oocyte 36; and supplementation of a tissue with exogenous 
mitochondria 37. Furthermore, there are many potential therapeutic strategies utilising gene 
therapies to deliver corrected versions of a defective gene, or to ectopically express proteins 
designed to degrade mutated mtDNA 38 or alter metabolism 39. While all these approaches 
could lead to potential treatments for common pathologies, their coverage is beyond the 
scope of this review, which will focus on the general strategies for the development of small 
molecule therapies that can modulate mitochondrial function.  
Drugs can act directly on the mitochondria themselves, or affect the organelle 
indirectly by binding to regulatory targets in the cytosol or nucleus 14,40. An important aspect 
of drugs that affect the organelle directly, is the ability to selectively target bioactive moieties 
to mitochondria in vivo by conjugation to lipophilic cations or to peptides, which facilitates 
drug effectiveness by enhancing potency, avoiding side effects and accelerating delivery 
14,20,41,42 (Box 2).  
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 There are five broad therapeutic strategies in which small molecules can be used to 
affect mitochondria directly or indirectly in secondary mitochondrial diseases. These are: (i) 
repairing or preventing damage to the organelle; (ii) inducing mitochondrial biogenesis; (iii) 
enhancing organelle quality control by stimulating degradation of damaged mitochondria or 
organelle components; (iv) co-opting mitochondrial function to induce  cell death; or (v) 
altering mitochondrial signaling pathways or metabolic processes. Below, we expand on 
these, but of course it is important to note that many of these types of damage are linked and 
that treating one mode of mitochondrial dysfunction often has a positive impact on others.  
 
Protecting mitochondria  
 
 
 
Mitochondrial dysfunction in diseases can arise from sustained damage to the organelle’s 
protein, DNA and lipids 2,43-45. Oxidative damage is frequently considered, due to the 
relatively high level of ROS production by the mitochondrial respiratory chain and the 
susceptibility of the organelle to oxidative damage 46,47. Carbon stress is another disruptor of 
mitochondrial function that arises due to the high levels of activated acyl-CoAs in the 
mitochondrial matrix that lead to non-enzymatic protein acylation, typically on lysine 
residues, that affects protein function and proteostasis 44,45,48.  
A related common pathway of mitochondrial damage in many scenarios is the 
depletion of NAD+, which can occur by activation of pathways that use up cellular and 
mitochondrial NAD+ pools, such as activation of poly (ADP-ribose) polymerases (PARPs), 
mono ADP ribosyl transferases, and the cyclic ADP-ribose hydrolase CD38  49,50 51  52. One 
consequence of NAD+ depletion is disruption of bioenergetic pathways. In addition,  NAD+ is 
required for the reversal of  lysine acylation by sirtuins, hence NAD+ depletion also 
contributes to an elevation of protein lysine acylation, disrupting signalling pathways that are 
altered by lysine acylation and also contributing to  carbon stress leading to  the accumulation 
of damaged and misfolded proteins.  Of course, many other forms of damage occur, for 
example disruption due to formation of the mitochondrial permeability transition pore 
(MPTP), a large conductance channel in the inner membrane that is activated following 
calcium accumulation in the presence of oxidative stress, leading to mitochondrial swelling 
and subsequent cell death 53-55.  
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Defects in mitochondrial proteostasis is another important form of mitochondrial 
damage that contributes to a wide range of pathologies 7 56 57.  Normally the proteins within 
the mitochondria are folded correctly and when they become damaged or miss-folded are 
either refolded or rapidly degraded 7 56 57. Thus, when correctly functioning, proteostasis 
prevents the accumulation and aggregation of defective proteins within mitochondria, which 
would severely disrupt organelle function.  Mitochondria face a number of challenges in 
maintaining proteostasis and maintaining the correct folding of proteins that are either 
imported into,  or translated within the organelle 57. A further complication is that four of the 
mitochondrial oxidative phosphorylation complexes contain polypeptides encoded by both 
the nuclear and mitochondrial genomes, hence the relative levels of these polypeptides have 
to be carefully matched to correctly assemble these complexes 57. Finally, the mitochondrial 
matrix is exposed to high levels of both oxidative and carbon stress, that can damage 
proteins, rendering  them less stable 57. In dealing with these challenges the mitochondria 
does not have a proteasome,  nor the same heat shock protein complement as the cytosol. 
Instead,   it has its own repertoire of chaperones and proteases to maintain organelles 
proteostasis 57 7 56. The mitochondrial chaperones include mitochondrial heat shock protein 
70 and 90 and the matrix chaperonin complex composed of mitochondrial  heat shock protein 
60 and 10 that help fold nascent proteins, or refold  misfolded ones. In addition, mitochondria 
contain a wide range of proteases that degrade misfolded proteins 58 7 56. Mutations in these 
mitochondrial proteases lead to the accumulation of misfolded proteins and dysfunctional 
mitochondria in a number of diseases 58. Furthermore, excessive oxidative damage, or protein 
acylation due to carbon stress, cause protein missfolding and aggregation within 
mitochondria. Thus factors such as replenishing the NAD+ pool to counteract carbon stress 
by enhancing the activity of sirtuins,  or preventing oxidative damage with antioxidants all 
help maintain  proteostasis. Due to the contribution of defective protostasis to common 
diseases there is considerable interest in activating chaperones or proteases at the level of the 
organelle. Related to this, the mitochondrion has an unfolded protein response (mtUPR) that 
upregulates the expression of  chaperones within the mitochondrial  matrix 57 56 and 
enhancing the activity of the mtUPR is protective in a number of  model organisms 56. 
Many drugs protect the organelle directly by affecting a specific process following 
selective binding to a particular target site. Some drugs target matrix proteins, for example, 
cyclosporin A binds to the matrix protein cyclophilin D (CyD) and thereby prevents cell 
death caused by formation of the MPTP 59. Other compounds such as suppressors of site IQ 
electron leak (S1QELs) and suppressors of site IIIQo electron leak (S3QELs) bind directly to 
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respiratory chain complexes I and III, respectively, in the mitochondrial inner membrane to 
inhibit ROS production 60,61. Conversely, there are many protective molecules that act on 
general processes within mitochondria, rather than by binding to specific targets 14,20. These 
include antioxidants designed to lower mitochondrial oxidative damage 62,  molecules that 
enable electrons to bypass respiratory complexes in order to sustain oxidative 
phosphorylation in spite of respiratory chain damage 63. A related intervention is the use of 
small molecule uncouplers such as dinitrophenol (DNP) which decrease the protonmotive 
force  (p) across the mitochondrial inner membrane thereby making oxidative 
phosphorylation less efficient, which helps to burn off excess fat and also to decrease  
mitochondrial ROS production 64 65.  The depletion of NAD+, which can lead to both 
bioenergetic defects and to  inappropriate protein acylation, can be counteracted by  
compounds such as nicotinamide (NAM), nicotinamide riboside (NR) and nicotinamide 
mononucleotide (NMN) which act by replenishing NAD+ levels 50-52,66-70.  Restoring NAD+ 
levels has a number of protective effects, in part by enhancing the activity of sirtuins which 
act as NAD+-dependent lysine deacylases. As protein acylation is thought to have a 
regulatory role in a number of metabolic processes, the positive effects of NAD+ modulators 
are often ascribed to changes in regulation 66,69. However, as lysine acylation is also a carbon 
stress that can lead to protein dysfunction and aggregation, it is also likely that some of the 
positive effects of elevating NAD+ levels and activating sirtuins are to counteract carbon 
stress  44,45.  
 
Altering mitochondrial biogenesis  
Instead of directly affecting mitochondria, an important alternative therapeutic strategy is to 
alter organelle amount or activity by enhancing mitochondrial biogenesis 15,71-73. This raises 
the possibility of pharmacologically increasing the mitochondrial content of the cell, the 
surface area of the inner membrane or the content of the oxidative phosphorylation 
machinery in order to increase mitochondrial ATP output, just as occurs in response to 
exercise 72. This could be achieved by pharmacologically intervening at the level of the 
transcription factors and related regulatory proteins that control mitochondrial biogenesis 
15,72,73. There are a large  number of nuclear-encoded transcriptional factors which control the 
expression of those genes involved in mitochondrial biogenesis. For example, Nuclear 
Respiratory Factors (NRF) 1 and 2 determine the expression of multiple nuclear genes that 
encode proteins targeted to mitochondria, such as DNA polymerase  (POLG) and the DNA 
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helicase Twinkle which are essential for mtDNA replication 74 and Transcription Factor A 
(Mitochondrial)  (TFAM) which regulates expression of the 37 genes encoded by mtDNA 
6,15. There are many other transcription factors that affect mitochondrial biogenesis, such as 
Peroxisome Proliferator-Activated Receptors (PPARs), Estrogen-Related Receptors (ERRs), 
and cAMP response element-binding protein (CREB1) and Forkhead box-O (FOXO)  7,15,72, 
however  a detailed consideration of these is beyond the scope of this review and is covered 
elsewhere 7. Transcription factor activity is further affected by the transcriptional coactivators 
such as  peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) and 
corepressors such as nuclear receptor corepressor 1(NCOR1), receptor interacting protein 140 
(RIP140) and retinoblastoma proteins (pRb) which helps to coordinate organelle biogenesis 
and oxidative metabolism in response to changes in cell metabolic requirements (reviewed in 
7,15 75). These responses are often transmitted through post translational modifications (PTMs) 
for example, phosphorylation of PGC-1α by the energy sensor AMP-activated protein kinase 
(AMPK)  increases  mitochondrial biogenesis in response to energy demand 13, while  PGC-
1α deacetylation by Sirtuin1 (SIRT1)  enables responses to metabolic challenges 75.  
 A number of drugs interact with these pathways to regulate mitochondrial biogenesis 
by altering the activity of transcription factors 72,73. For example, the PPARγ transcription 
factor can be activated directly by the anti-diabetic drugs pioglitazone and rosiglitazone, as 
well as by the lipid metabolism modifiers bezafibrate and thiazolideindiones, which increase 
PGC-1α expression and upregulate mitochondrial biogenesis 15,76 7 
 77. Mitochondrial biogenesis can also be enhanced by drugs that alter PGC-1α activity 
indirectly 15 75. For example, AMPK agonists such as 5-aminoimidazole-4-carboxamide 
ribonucleotide (AICAR) activate PGC-1, mimicking the enhancement of mitochondrial 
biogenesis by energy demand 78. Another approach is to use the SIRT 1 activators resveratrol 
and viniferin, which activate PGC-1 by reversing acetylation 15. A parallel approach to 
enhancing mitochondrial biogenesis is to inhibit pathways that repress mitochondrial 
biogenesis, such as hypoxia-inducible factor-1α (HIF-1α) 79,80.  
 
Modulating mitochondrial dynamics  
Mitochondria do not exist as isolated organelles in the cell, but instead undergo a continual 
cycle of fusing together to form larger mitochondria that then undergo fission to break up into 
smaller bodies 81,82. The protein machinery that leads to these processes comprises fission 
proteins such as dynamin related protein 1 (DRP-1), while fusion is determined by proteins 
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such as mitofusins (MFN 1 & 2) on the outer membrane and Optic Atrophy 1 (OPA1) on the 
inner membrane 82 81. Small molecules have been developed such as mitochondrial division 
inhibitor-1 (Mdivi-1), which decrease DRP-1 activity and thus slow mitochondrial fission 
77,83, however their specificity is unclear hence some effects may not be due to affecting 
organelle division 84,85. Modulating mitochondrial dynamics is thought to have a number of 
beneficial impacts on mitochondrial function and activity, although in many cases the 
mechanism and significance of these effects are not clear 77.  However, it is evident that one 
important aspect of mitochondrial dynamics is that it is intimately linked to  mitochondrial 
quality control, discussed below.    
 
Enhancing mitochondrial quality control 
A major reason for continual mitochondrial fission/fusion is that it facilitates the degradation  
of damaged organelles by mitophagy, because small mitochondrial particles can be easily 
engulfed by the mitophagy machinery  71 81,82. This requires a means of recognizing that 
mitochondria moving through the small particulate stage are damaged. One way in which this 
may be done is by their lowered protonmotive force (p) which leads to accumulation of the 
kinase PINK on their surface, PINK in turn recruits the PARKIN E3 ligase which 
ubiquitinylates damaged mitochondria and thereby targets them for degradation by 
mitophagy 86.  While the role of this pathway in vivo is less clear 87,  pathways that recognise 
damaged mitochondria and target them for mitophagy are a central part of mitochondrial 
quality control. Thus, drugs that enhance mitochondrial division may increase the clearance 
of defective organelles 71 81,82. One example is AMPK activation which can increase DRP-1 
recruitment to mitochondria by direct phosphorylation of the mitochondrial adaptor, 
mitochondrial fission factor (MFF), and thus enhances fission and subsequent autophagy of 
damaged mitochondria 13,88. Increasing the removal of damaged mitochondria by mitophagy 
has many positive effects, such as decreasing inflammation 71, thus activating mitophagy is 
an appealing therapeutic strategy and this has been explored with promising results using 
natural compounds such as Urolithin A which enhances muscle function in rodents with 
possible relevance to sarcopenia  89.  
There are many other ways in which mitochondria quality control can happen at the 
sub-mitochondrial level in parallel to mitophagy. Correct mitochondrial proteostasis protects 
against the accumulation of damaged and unfolded proteins within mitochondria 57 56.  
Prevention of mitochondrial protein aggregation can be enhanced by upregulating the mtUPR 
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response,  which increases the expression of a series of chaperones within the mitochondria 
and activating this response is protective in a number of  model organisms 56. 7. Mitochondria 
can compartmentalize oxidized protein and lipid into mitochondria-derived vesicles (MDVs) 
that bud off  from the organelle and are then targeted for degradation in lysosomes 90-92. 
There are also multiple proteases, nucleases and lipases within the mitochondria that degrade 
damaged molecules 58. Among these are the proteases ATPases associated with diverse 
cellular activities (AAA) proteases, mutations to which contribute to degenerative diseases 58. 
Finally, the myriad of potentially disruptive small molecules generated within mitochondria 
by oxidative damage and carbon stress can be conjugated to glutathione by glutathione S-
transferases and the resulting conjugate exported by ATP Binding Cassette (ABC) proteins 93. 
Thus enhancing the clearance of damaged mitochondria and the organelle’s components is a 
promising strategy for future development.  
 
Harnessing mitochondria to kill cells  
The central role of mitochondria in cell death by apoptosis or necrosis makes them a good 
target when aiming to kill a particular cell 55,94, such as a cancer cell or a protozoan parasite. 
While it is easy to kill cells non-selectively by targeting mitochondria, the challenge is to do 
so selectively. Mitochondria are similar in most cells, consequently any small differences in 
the mitochondrial function of target cells makes an appealing target 95. Therefore, using 
mitochondria to kill cancer cells necessitates focussing on how they differ from non-
transformed cells, or selectively activating a toxic  pro-drug within the target cell. For 
example, many cancer cells have ineffective mitochondrial apoptosis that can be re-activated 
96. Another approach is to deplete antioxidant defences 97, or to increase mitochondrial ROS 
production 98, and combine these cell stressors with another cancer drug to induce synthetic 
lethality 97.  
 
Altering mitochondrial signaling  
A rapidly expanding area of mitochondrial biology is the role of the organelles as signaling 
hubs that respond to and influences processes throughout the cell 6,99,100. The signals that 
emanate from mitochondria to the rest of the cell include changes in ATP/ADP ratio, Ca2+, 
NAD+, metabolites and ROS, but our understanding of their nature, targets and physiological 
roles is still developing 99. Redox signaling by the production of ROS such as hydrogen 
peroxide, that modify protein activity through the reversible oxidation of redox sensitive 
cysteine residues has been a long standing focus 99,101,102. More recently there has been 
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considerable interest in how citric acid cycle (CAC) metabolites are transmitted back and 
forth between the mitochondrion and the cytosol as a way of regulating cell function and fate 
103,104. For example, histone acetylation is sensitive to acetyl CoA levels that are determined 
by citrate export from the mitochondria 105. Furthermore, there are numerous 2-oxoglutarate-
dependent dioxygenases, including: prolyl hydroxylases in the Hif-1 oxygen sensing 
pathway; Ten Eleven Translocation (TET) DNA demethylase; and the histone lysine 
demethylase Jumonji C 106. These enzymes utilise 2-oxoglutarate as a substrate and are 
inhibited by succinate, hence providing a link between mitochondrial CAC activity and the 
regulation of oxygen sensing and the formation of epigenetic marks on the genome 106  106 107. 
Thus, the manipulation of CAC metabolite transfer between the mitochondrial matrix and the 
rest of the cell may be a useful therapeutic approach 108.  
 
Treating pathologies via mitochondria 
 
The general principles of how and why to treat mitochondria in common pathologies have 
been outlined above. Here we consider some concrete examples of the common pathologies 
ischemia-reperfusion injury, inflammation, the metabolic syndrome, neurodegeneration, heart 
failure and protozoal infection where therapies focussed on mitochondria are likely to be 
effective, discuss the approaches used and suggest future directions. Mitochondria are also 
proving to be an interesting therapeutic target in cancer therapies,  however  the diversity of 
this field puts it beyond the scope of this review but a few key points are considered in Box 3. 
Mitochondria are also emerging as potential targets in many other common pathologies 
including muscular dystrophies 69, sarcopenia 109, lung diseases 110 and colitis 111 and the 
reader is referred to the cited papers and reviews for more detail. 
 
Ischemia-reperfusion injury  
 
Ischemia ensues when the blood flow to an organ is disrupted, depriving it of oxygen and its 
supply of external metabolites, while also causing a build-up of metabolic products such as 
lactate and succinate 112 113,114 115 (FIG. 2). The lack of oxygen and respiratory substrates 
stops oxidative phosphorylation causing the ATP/ADP ratio to fall, which in turn leads to 
adenine nucleotide breakdown 116. The obvious remedy for ischemia is to restore blood flow 
as quickly as possible to the affected tissue. For example, the standard of care for the most 
damaging form of heart attack, ST-Elevation Myocardial Infarction (STEMI) is to remove the 
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blockage from the cardiac artery by Primary Percutaneous Coronary Intervention (PPCI) 30.  
Despite prompt reperfusion by PPCI, extensive tissue damage known as ischemia-reperfusion 
(IR) injury is still a major cause of morbidity and mortality 117, thus, a major unmet need is a 
treatment that can be administered to the patient at the same time as PPCI 30 117. Similarly, in 
ischemic stroke the standard of care is to restore blood flow through thrombolysis by infusion 
of tissue plasminogen activator (TPA) 118 or by angiographic revascularisation 119. These 
interventions rapidly restore blood flow, but paradoxically the restoration of oxygenated 
blood to the ischemic tissue itself leads to IR injury 112 113,114 115,120. IR injury is a key driver 
of pathology in heart attack and stroke 112,114,115, but also in many other pathologies, including 
acute kidney injury 121, muscle injury 122 and the organ damage associated with organ 
transplantation and elective surgery 123. While there has been considerable clinical progress in 
minimising the duration of ischemia in many pathologies, there is now increasing interest in 
developing therapies that decrease the inevitable IR injury that occurs on reperfusion of 
ischemic tissues 115.  
Mitochondrial ROS production in IR injury. The initiating factor of IR injury is a 
burst of the ROS, superoxide from the mitochondrial respiratory chain upon reperfusion that 
initiates a cascade of tissue damage 114,115. This process had long been tacitly assumed to be a 
random consequence of the reperfusion of ischemic tissue, however, recent work suggests 
that IR injury occurs as a result of specific processes and is not just a catastrophic breakdown 
of cell function 114,124 (FIG. 2). During ischemia, the CAC metabolite succinate builds up 
dramatically, then upon reperfusion the accumulated succinate is rapidly oxidised driving 
superoxide production at complex I by reverse electron transport (RET) (FIG. 2) 114. The 
superoxide production results in oxidative damage that disrupts mitochondrial function, and 
in conjunction with calcium accumulation within mitochondria during ischemia, leads to 
induction of the MPTP 125-127. The cell death and organ dysfunction caused by induction of 
the MPTP leads to the release of mitochondrial and cell contents, resulting in the activation 
of an inflammatory response that can further damage tissue and will ultimately give rise to 
tissue scarring and remodelling 128. Whether or not this model of IR injury stands the test of 
time, it seems to account for much of the confusing literature in the field, and can be used to 
generate rational therapies and provides a useful framework for discussing mitochondrial 
therapies for IR injury 114 (FIG. 2).  
Metabolic changes in IR injury. Succinate accumulation during ischemia and its 
oxidation during reperfusion are key drivers of IR injury 129-131. Malonate is a potent inhibitor 
of succinate dehydrogenase (SDH) and its cell-permeable form dimethyl malonate (DMM) 
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both decreases succinate accumulation during ischemia and its oxidation upon reperfusion 
129. Furthermore addition of malonate upon reperfusion is also protective 130,131. In addition, 
some succinate is released from the ischemic tissue into the circulation upon reperfusion 132 
and can activate  the pro-inflammatory succinate receptor (SUNCR1) which is expressed in 
immune cells, thereby stimulating inflammatory damage 133-135. These findings suggest that 
inhibitors of succinate accumulation during ischemia, and its oxidation and release during 
reperfusion are promising therapeutic agents 136.  
Complex I as a target in IR injury. Succinate oxidation upon reperfusion generates 
ROS at complex I by RET and this ROS production can be blocked with the complex I 
inhibitors rotenone 137, with  S1QELs 61, or by the mild uncoupling of mitochondria in order 
to lower p, a driving force for RET 138. These findings suggest that inhibiting RET at 
complex I transiently during reperfusion blocks the ROS burst, with complex I activity 
returning to normal when the accumulated succinate during ischemia has been oxidised. For 
example, inhibiting complex I temporarily during reperfusion with the mitochondria-targeted 
S-nitrosating agent MitoSNO decreases cardiac IR injury in mice  139-141. The reversible 
inhibition of complex I is brought about by S-nitrosating a particular cysteine residue that is 
only exposed during ischemia when complex I undergoes a conformational shift to a deactive 
state 141. S-nitrosation temporarily locks complex I in the deactive state, preventing RET 
upon reperfusion, but as the modification is reversible, the activity of complex I is restored to 
normal a few minutes after reperfusion 141. It is likely that many other agents that protect 
against IR injury, such as hydrogen sulfide 142,143, act in a similar way to decrease ROS 
production upon reperfusion 114.  
The next point of intervention is to protect mitochondria from oxidative damage 
during IR injury 144. Exogenous antioxidants are protective against IR injury 144, and 
mitochondria-targeted antioxidants have also shown protection against cardiac 145 146 and 
kidney 147 IR injury. However, a limitation is that the antioxidant was administered prior to 
IR injury, and it may not be taken up rapidly enough to be effective when added upon 
reperfusion to treat heart attack or stroke. Even so, mitochondria-targeted antioxidants may 
be useful for situations where IR injury is predictable, such as elective surgery or organ 
transplantation.  
The MPTP in IR injury. Blocking MPTP induction is the next point to protect 
mitochondria during IR injury 125-127. While the nature of the MPTP is still not definitively 
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established, it is clear that the mitochondrial cis-trans prolyl isomerase CyD is required for 
induction of the MPTP under pathological conditions 125-127.  
The MPTP can be blocked by infusion of the CyD inhibitor  CsA at reperfusion 148, 
immediately suggesting a drug treatment for IR injury in humans. When CsA was 
administered at the same time as PPCI in a Phase II trial of STEMI patients it showed 
promising results 149. However, when extended to Phase III in the CIRCUS 26 and CYCLE 
trial 27, it was unsuccessful. The drug TRO40303, which binds to mitochondrial outer 
membrane translocator protein (TSPO) and is thereby thought to inhibit the MPTP, was also 
unsuccessful against STEMI in the MITOCARE study 150 151. The mitochondria-targeted 
peptide Bendavia (SS31) showed promising results against IR injury in animal studies 152, 
although its mechanism of action is unknown, but it too was unsuccessful when administered 
to STEMI patients during PPCI in the EMBRACE STEMI study 24.  
Translation of IR therapies to the clinic. While treatment of IR injury with 
mitochondrial therapeutics is well justified by animal studies, when it was attempted in a 
well-defined clinical scenario – PPCI of STEMI patients – the outcome has so far been 
disappointing 153. There are several factors contributing to this 30: the animals used were 
young and healthy, lacking the co-morbidities of old and unhealthy patients; patients are on 
multiple medications that may act on the same pathways as the drugs being assessed, offering 
little scope for further protection; the duration of ischemia prior to treatment may have been 
too short, so the tissue will fully recover anyway, or too long, making salvage of the organ 
impossible; the uptake of drugs such as CsA into mitochondria may have been too slow to 
stop the cell damage, hence the need to administer the drugs very rapidly to the tissue. For 
many of the drugs investigated so far, administration must occur at the time of or very shortly 
after the onset of reperfusion. Clinical trials should be designed more carefully to address 
these pitfalls 117,154. Despite the disappointments we believe that therapies targeted at 
preventing ROS production upon reperfusion 141 129 130,131 have potential in humans, either 
alone or as part of a combination therapy targeted to multiple nodes of mitochondrial damage 
during IR injury.  
In summary, preventing mitochondrial damage during IR injury remains a promising 
treatment strategy and the hope is that treatments focussed on mitochondria will lead to new 
therapies for a range of pathologies. The common mitochondrial pathway for IR injury 
suggests that many of the therapies under development can be applied to other clinical 
situations when IR injury arises, such as elective surgery, organ transplantation, acute trauma, 
or stroke. Using mitochondrial therapies to treat stroke is particularly appealing as such 
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treatments can be given safely to patients  prior to a brain scan in hospital, which is 
mandatory before thrombolysis or thrombectomy to determine if it is an ischemic or 
hemorrhagic stroke. IR injury in stroke is far less investigated than in myocardial infarction 
(MI) and the translation of protective strategies has been frustratingly slow. Furthermore, 
while mortality and morbidity for MI has declined in recent years due to early reperfusion, 
this is not the case for stroke, so focussing on  mitochondria  may help address this unmet 
need.    
 
Pathological Inflammation 
Inappropriate activation of inflammation contributes to the aetiology of many common 
disorders, ranging from the acute inflammatory response in sepsis, to the chronic 
autoimmune diseases multiple sclerosis (MS), lupus and rheumatoid arthritis 120 4,155. 
Mitochondria contribute to inflammation by contributing to the tissue damage that leads to 
inflammation and also by their role as signaling hubs in key immune cells such as T cells and 
macrophages 4,156. Resting monocytes/macrophages and lymphocytes rely on oxidative 
phosphorylation but following immune activation, their metabolism is reprogrammed to 
aerobic glycolysis and glutaminolysis to support cell proliferation 110,157 4. Thus, new 
therapies targeted to mitochondria are a promising way to intervene in disorders associated 
with inflammation 110 4,157.  
Mitochondria play an important role in the activation of innate immune signaling 
29,110. Due to their endosymbiotic origin from -proteobacteria, mitochondria can be 
considered as ancient ‘enemies within’ that only reveal themselves as such when their 
contents are released 29. These mitochondrial components are then recognized as Damage 
Associated Molecular Patterns (DAMPs) by the innate immune system, akin to the Pathogen 
Associated Molecular Patterns (PAMPs) that activate the innate immune system in response 
to bacterial or viral infections 29. DAMPS released by mitochondria include N-formyl 
peptides, which are made during mitochondrial (and bacterial) protein synthesis, but not by 
eukaryotic cytoplasmic ribosomes 158. Another important DAMP is mtDNA, on which CpG 
islands are hypomethylated compared to those on eukaryotic nuclear DNA, but again is 
similar to bacterial and virus DNA 158. Mitochondrial DAMPs also provide a signal to initiate 
repair following tissue injury by binding to receptors of the innate immune system, they 29. 
These mitochondrial DAMPs can act both within the cell, or following their release into the 
circulation 159. In many disorders this immune activation by tissue damage contributes to the 
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pathology. Hence, many approaches that protect against mitochondrial damage, such as 
antioxidants or CsA, exert some of their clinical benefit by decreasing immune activation 
through limiting the release of mitochondrial DAMPS 114. Mitochondria contribute to the 
initiation of inflammatory signaling pathways within cells in a number of ways. One way is 
through the assembly of the NOD- LRR- and pyrin domain-containing protein 3 (NLRP3) 
inflammasome on the surface of the mitochondrial outer membrane in response to 
mitochondrial damage and elevated ROS levels, leading to the maturation of pro-
inflammatory cytokines such as IL-1  and Il-18 160 4 161. These inflammatory pathways can 
also be activated in response to viral infection through the mitochondrial antiviral signaling 
(MAVS) pathway on the mitochondrial outer membrane 29,162. Thus mitochondria are 
involved in many ways in the activation of innate immune signalling in a number of ways.  
Mitochondria also play an important role in the adaptive immune response, for 
example CD4+ helper T cells and cytotoxic CD8+ T cells reprogram their metabolism away 
from oxidative phosphorylation to aerobic glycolysis and glutaminolysis, which supports 
elevated mitochondrial ROS production and cytokine production that enables subsequent T 
cell proliferation, and is sustained through epigenetic changes 4,156,163. Mitochondrial 
metabolism in macrophages is also reprogrammed in a similar way when they shift from the 
anti-inflammatory M2 phenotype to the pro-inflammatory M1 phenotype in response to 
infection and tissue damage, subsequently returning to the M2 phenotype to help resolve the 
inflammation 4. The shift of macrophages to the M1 phenotype is associated with elevated 
succinate generation by mitochondria, which stabilizes Hif-1, and also generates 
mitochondrial ROS by RET at complex I 104,164. Together these signals activate downstream 
transcriptional pathways that sustain macrophage proliferation and cytokine production in 
response to infection or tissue damage 104,164. In addition, upon its release from cells into the 
plasma succinate acts as a pro-inflammatory signal, by binding to SUNCR1, a G-protein 
coupled receptor on the surface of cells in the retina, kidney and immune system which 
responds to extracellular succinate to activate a proinflammatory signaling pathway 135,165.  
In summary, mitochondrial damage, elevated ROS production and succinate 
generation are frequently associated with inflammation. Therefore, pharmacological 
interventions that decrease mitochondrial damage or alter signaling pathways by decreasing 
mitochondrial ROS production and succinate generation/oxidation may prevent an excessive 
immune response. Supporting this, animal models of sepsis have shown that mitochondria-
targeted antioxidants 166,167 and inhibitors of succinate oxidation 164 are protective. 
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Furthermore, mitochondria-targeted antioxidants have also shown efficacy in animal models 
of autoimmune diseases such as multiple sclerosis and tumor necrosis factor receptor periodic 
disease (TRAPs) 157,168. While these approaches have yet to be translated to the clinic, they 
suggest that therapies focussed on mitochondria are an emerging way of limiting pathological 
inflammation.  
 
The metabolic syndrome  
The metabolic syndrome comprises a cluster of symptoms including central obesity, insulin 
resistance, elevated blood pressure and raised levels of circulating glucose, triglycerides and 
cholesterol 169,170. The metabolic syndrome is at epidemic levels in both the developed and 
developing world, greatly increasing the risk of pathologies including type 2 diabetes, heart 
attack, stroke, fatty liver and heart failure, with considerable economic, social and medical 
consequences 169. Although lifestyle changes could address many cases of the metabolic 
syndrome, there remains a huge unmet need for better treatments to, ideally, address the 
underlying pathology, or at least ameliorate the symptoms. As over-nutrition and lack of 
physical activity are frequently associated with the metabolic syndrome it is unsurprising that 
mitochondrial dysfunction is central to its development 170,171.  
 Obesity. Central obesity is a key component of the metabolic syndrome, and 
decreasing obesity by bariatric surgery is an effective treatment for the metabolic syndrome 
172, hence reducing obesity pharmacologically is appealing medically, as well as aesthetically 
65. An obvious way to decrease adipose tissue is to burn off stored fat as heat 173.  Uncoupling 
protein 1 (UCP1) in brown adipose tissue releases the chemical potential energy stored in fat 
as heat rather than as a high ATP/ADP ratio 65. This occurs because UCP1 facilitates 
increased proton movement through the mitochondrial inner membrane, thereby making 
oxidative phosphorylation less efficient 173. Small molecule protonophoric uncouplers such as 
dinitrophenol (DNP) are very effective at decreasing obesity in humans in this way 65,174.  
However, in 1938, the FDA banned use of   DNP as a slimming agent because its narrow 
therapeutic window led to cases of fatal hyperthermia 64,65,174. Thus, a safe mitochondrial 
protonophore with a far wider therapeutic index than DNP has considerable appeal for 
treating the metabolic syndrome 65. One promising approach is through a DNP methyl ether 
that is preferentially metabolised to DNP by cytochrome P450s in the liver, selectively 
releasing DNP and decreasing fatty liver disease, hyperlipidemia and insulin resistance with 
far less toxicity than DNP 174 175,176. An alternative approach is to use a self-limiting 
protonophore that would only induce proton leak in mitochondria with a high p, but which 
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would then inactivate itself once the p decreased systems 177,178. It may also be possible to 
enhance uncoupling by activating endogenous mitochondrial proteins to dissipate the p, for 
example by cysteine modification of UCP1 in brown adipose tissue 179. Mitochondrial 
oxidative phosphorylation could also be made less efficient by allowing electrons to bypass 
proton pumping respiratory chain complexes, as is achieved by the direct transfer of electrons 
from the CoQ pool to oxygen using the alternative oxidase (AOX) in plants and protozoans 
39. However, replicating this process with small molecules without generating ROS is a major 
challenge. Oxidative phosphorylation can also be rendered less efficient by degrading ATP 
non-productively in a futile cycle, which is how shivering generates heat. There are 
interesting recent reports that creatine phosphate can be hydrolysed in this way 180,181, but 
whether this process can be pharmacologically manipulated is not yet known. It may also be 
possible to enhance ATP hydrolysis more directly, the potential of which is illustrated by 
arsenate which substitutes for phosphate during mitochondrial ATP synthesis to form ADP-
arsenate which hydrolyses spontaneously 182 183. In summary, decreasing mitochondrial 
efficiency is an appealing strategy to treat the metabolic syndrome which has been tainted by 
its past association with the unregulated use of DNP as a slimming pill 65. Promising new 
approaches with enhanced selectivity are emerging, so it should be possible to gradually 
decrease obesity without dangerously disrupting energy metabolism 175,176.  
 Insulin resistance. Another hallmark of the metabolic syndrome is insulin resistance 
whereby tissues, notably skeletal muscle, are less effective at taking up glucose in response to 
insulin and liver glucose output is not shut down 16. Metformin is a widely used drug for type 
II diabetes which inhibits complex I, elevates the ADP/ATP ratio and thereby activates liver 
AMPK to slow liver gluconeogenesis 184. Mitochondrial dysfunction has long been associated 
with insulin resistance, however the mechanism is not known and it is unclear whether 
defective mitochondrial function is a cause or consequence of insulin resistance 171. Even so, 
there is considerable circumstantial evidence linking elevated mitochondrial ROS production 
and organelle dysfunction with insulin resistance, as well as with ectopic lipid accumulation 
and chronic inflammation 185 171,186. This is supported by studies where decreasing 
mitochondrial ROS production and oxidative damage by the use of mitochondria-targeted 
antioxidants restored insulin sensitivity and attenuated associated factors such as 
hyperlipidemia 187 188,189. Chronically elevated blood glucose leads to a range of 
complications in both type I and II diabetes, including microvascular disease damaging small 
blood vessels that particularly affects the retina, peripheral neurons and the kidney 190 16. 
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Increased mitochondrial ROS production is thought to be one consequence of the elevated 
glucose 190 191. Consistent with this, mitochondria-targeted antioxidants have shown promise 
in decreasing diabetic complications 16. Furthermore, in mouse models of type 2 diabetes 
there is depletion of the NAD+ pool and ameliorating this with  NMN has shown efficacy 70, 
suggesting that the bioenergetic and proteostatic defects associated with NAD+ depletion 
contribute to the metabolic syndrome and that restoring the NAD+ pool is a promising 
therapeutic approach.  
 
 Hypertension. Mitochondrial oxidative damage and elevated production of 
superoxide in endothelial cells is a contributing factor to the elevated blood pressure seen in 
the metabolic syndrome 192. This elevation in blood pressure is thought to occur due to 
mitochondrial superoxide reacting with and thus sequestering the vasorelaxant NO 193. In 
addition, the elevated production of ROS leads to oxidative damage to extracellular elastase 
192, which also contributes to hypertension. These findings suggest that decreasing 
mitochondrial ROS production and preventing the associated oxidative damage is a potential 
therapy for hypertension. Supporting this view, the administration of mitochondria-targeted 
antioxidants to rodents was shown to lower blood pressure  193,194 195. These studies also 
indicated that the positive effects on hypertension were associated with less mitochondrial 
ROS production, consistent with a key role for mitochondrial oxidative stress in 
hypertension. One limitation to these studies was that the mitochondria-targeted antioxidants 
were given while the hypertension developed in the animals, rather than reversing the 
hypertension once it was established. This was addressed in a study with old (~ 27 month 
old) mice with established aortic stiffness where treatment for 4 weeks with MitoQ reversed 
this 196. This was then extended to older human volunteers (60 – 79 years of age) with 
impaired endothelial function indicated by impaired brachial artery flow-mediated dilation 
197. In this placebo-controlled crossover design study it was found that 6 weeks of oral 
supplementation with MitoQ improved brachial artery flow-mediated dilation 197. These 
studies suggest that mitochondria are a promising therapeutic target for hypertension. 
 Non Alcoholic Fatty liver disease (NAFLD).  NAFLD is frequently associated with 
the metabolic syndrome, both as a consequence and as a contributor to the pathology 198. 
NAFLD comprises a range of pathologies, beginning with fatty liver, or steatosis, and 
progressing to nonalcoholic steatohepatitis (NASH), which in turn often leads on to liver 
fibrosis and finally to cirrhosis 198,199.  NAFLD is the most common form of chronic liver 
disease in the western world and is strongly associated with obesity. Treatment options for 
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NAFLD are limited, with liver transplantation being the only possibility for cirrhosis 198.  The 
accumulation of fat in the liver is the key driver of NAFLD and this can be addressed directly 
by enhancing mitochondrial fat oxidation by inducing selective mitochondrial uncoupling in 
the liver using DNP derivatives 175,199. In addition, mitochondrial damage is intimately linked 
to the development of NAFLD, with elevated oxidative stress and NAD+ depletion 51,200. 
Consequently in animal models of NAFLD there have been demonstrations of efficacy with 
mitochondria-targeted antioxidants such as MitoQ  187 188,189 as well as with NMN which 
replenished the NAD+ pool 51. Thus treatments aimed at enhancing mitochondrial fat 
oxidation, or protecting mitochondria against damage are both appealing strategies for 
treating NAFLD.  
 
Neurodegenerative diseases 
Most current treatments for neurodegenerative disorders are aimed at alleviating symptoms, 
therefore therapies that slow or stop the progression of the neurodegeneration are desperately 
needed 120,201-203 120 204 205 15. However, the search for disease modifying treatments is 
hampered by our limited knowledge of neuronal cell death mechanisms in these disorders, 
even when the gene responsible is established, as in Huntington’s disease (HD) and familial 
Parkinson’s Disease (PD). Even so, there is a long standing and robust consensus that 
mitochondrial dysfunction is strongly associated with a wide range of neurodegenerative 
diseases, including PD, Alzheimer’s Disease (AD), Amyotrophic Lateral Sclerosis, HD and 
Friedreich’s Ataxia 77,120,202,203 120. This association between mitochondrial dysfunction and 
neurodegeneration is supported by in vitro studies, genetic and toxin animal models, post 
mortem human brain tissue and human genetic studies 206,207 120,202,203 120 204. Many types of 
mitochondrial dysfunction have been associated with neurodegeneration, including oxidative 
damage, defective ATP synthesis, NAD+ depletion, limited mitochondrial dynamics and 
quality control, disrupted calcium homeostasis and the association of protein or peptide 
aggregates with mitochondria 202,203 120 202.  
Thus, there is a clear consensus that mitochondrial dysfunction is closely associated 
with neurodegeneration, but whether organelle dysfunction is a cause, a consequence or part 
of a self-sustaining vicious cycle of damage is difficult to deconvolute. However, resolving 
these issues is not essential for drug development, as therapies that protect mitochondria 
work in genetic and toxin animal models of neurodegenerative disorders 202,206 31 208. Among 
the  treatments that are protective against mitochondrial damage and have shown efficacy in 
animals are antioxidants such as CoQ10, mitochondria-targeted antioxidants such as MitoQ, 
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and  mitochondria-targeted peptides such as Bendavia (SS31)  209,210. Therapies that enhance 
mitochondrial biogenesis by increasing the activity of transcription factors such as PGC1 
and NRF2, or of AMPK are also effective in animals models 203. In addition, replenishing 
NAD+ pools with molecules such as NMN 67 or altering mitochondrial dynamics 211 212, have 
also shown benefit in animal models. Of particular interest is the potential to use these 
interventions to address defects in mitochondrial proteostasis, which contribute to a range of 
neurodegenerative diseases  68 213. 
Despite these promising data in animals, the translation of mitochondrial therapies to 
the clinic has been disappointing 31. For example, creatine, CoQ10 and NRF2 were ineffective 
in PD or AD 202 214,215 77 and the mitochondria-targeted antioxidant, MitoQ showed no effect 
in PD 23. Why the lack of success? In our view the extensive animal and human data indicate 
that targeting mitochondria is a good strategy that should slow the progression of 
neurodegenerative diseases. A likely factor contributing to the lack of success to date is that 
by the time a patient with a neurodegenerative disease is recruited to a clinical trial, the 
pathology is already too firmly established to be treated. In contrast, in many animal studies, 
therapies are given before the onset of clinically evident symptoms. Related to this, many 
neurodegenerative disease processes may constitute a vicious spiral, such that once the cell 
damage is initiated, other factors, such as inflammation and vascular damage contribute to a 
feed forward spiral of death. Thus, by the time the disease is symptomatic it may already be 
too late to intervene at the level of the mitochondria.   
Possible ways to improve the translation of mitochondrial drugs to the clinic are to 
screen compounds in animal models after neurological symptoms are well established, to 
determine if the drug can slow progression before moving to human trials. A corollary is the 
urgent need for early diagnosis in as-yet-asymptomatic patients so that clinical trials can be 
initiated well before irreversible damage has occurred. In the absence of presymptomatic 
diagnosis, we can focus trials on patients with a strong likelihood of developing a 
neurodegenerative disease, such as those with HD 216, Down’s syndrome 217, familial forms 
of PD 218, or subjects predisposed to AD due to the presence of the homozygous 4 allele of 
apolipoprotein E 219. We remain optimistic about the potential of mitochondrial therapies for 
the treatment of neurodegenerative diseases, particularly those designed to prevent 
mitochondrial damage, increase organelle biogenesis or enhance mitochondrial quality 
control. However, these developments require advances in early diagnosis, the development 
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of clinically relevant biomarkers and improved trial design to enable the faster evaluation of 
compounds in the clinic. 
 
Retinal dysfunction. An important subset of neurological diseases that have a strong 
mitochondrial component are those due to retinal defects 220 221.  Damage or loss of retinal 
photoreceptor cells (RPCs) is the most common cause of sight loss in the western world, with 
the most prevalent form  being  age-related macular degeneration (AMD) 220 221. The most 
common, “dry” form of AMD is caused by loss of retinal pigment epithelia (RPE) cells that 
sustain photoreceptor cells 221. In addition, there are a number of inherited conditions that 
predispose to photoreceptor loss,  the most common of which  is  retinitis pigmentosa (RP) 
220. The RPCs, RPE and Müller glial cells all contain large amounts of mitochondria making 
the retina one of the most oxidatively active tissues 222 223. In addition, the retina is exposed to 
high levels of oxidative stress due to light exposure  224.   The dependence on oxidative 
phosphorylation and high levels of oxidative stress  make the retina very susceptible to 
mitochondrial dysfunction and suggests that treatments focussed on this organelle may be 
beneficial 222.  This is supported by findings in animal models showing that PRC death is 
associated with NAD+ depletion, leading to decreased sirtuin 3 activity,  and that NAD+ 
repletion with NMN decreases this cell loss  52. Furthermore, treatment with a mitochondria-
targeted antioxidant in an animal model of AMD decreased oxidative stress and inflammation 
225. While  a number of challenges remain, such as the  selective delivery of molecules to the 
retina,  preliminary data and the  importance of mitochondria in retinal pathologies suggest 
that this is an important  area for future development.  
 
Heart failure  
There are multiple causes and variants of chronic heart failure (HF) 226, but in all cases it 
leads to progressive cardiac dysfunction and inadequate blood pumping 227-229 230. Current 
treatments for HF include beta blockers, angiotensin converting enzyme inhibitors, 
vasorelaxants and diuretics, which predominantly act by lowering the work load on the 
failing heart 231 232. Drugs capable of improving heart contractility and blood pumping in HF 
without the adverse effects associated with positive inotropic therapy are needed 32. 
The energy-demanding blood pumping by the heart relies on mitochondrial ATP 
production to both drive cardiomyocyte contraction and redistribute the calcium released to 
initiate this process 233. Metabolic supply and demand are closely matched so that the heart 
can adapt rapidly to the 5-6-fold increase in workload required for maximum physical 
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activity 233. Hence, it is unsurprising that mitochondrial dysfunction is a key component of 
HF 234 230 227-229. This is illustrated by the metabolic remodelling in the failing heart which 
shifts from fatty acid oxidation towards glucose utilisation because it produces more ATP per 
oxygen consumed than fat 235. There are multiple factors leading to mitochondrial 
dysfunction in HF, but elevated ROS production and oxidative damage 227-229, and defective 
mitochondrial biogenesis 236 are recurring themes, although whether these are causes or 
consequences of HF is less clear 237.  
Mitochondrial dysfunction in HF could be targeted by preventing mitochondrial 
damage, increasing mitochondrial biogenesis or enhancing the ATP output of the remaining 
mitochondria 230 238 32,226 239 230. As mitochondrial ROS production and oxidative damage has 
been found repeatedly in HF, the use of antioxidants to prevent this damage is an appealing 
strategy. While this approach has worked in animal trials of HF, on translation to humans the 
results have generally been disappointing 230,239. One way to enhance antioxidant 
effectiveness may be to target them to mitochondria 230,239, and supporting this possibility, 
MitoQ 193 and the mitochondria targeted peptide Bendavia (SS31) have shown efficacy in 
animal models of HF 238,240,241. More positively, the Q-SYMBIO trial showed that using 
CoQ10 as an antioxidant improved heart function 25, although larger trials are required. 
Upregulating mitochondrial biogenesis, for example by activating PGC-1 242, are further 
potentially interesting approaches 226. Thus, therapies targeted at protecting mitochondria or 
increasing their biogenesis in HF are promising areas for future development 230.  
 
Protozoal infections 
Protozoal infections are responsible for a number of medically, socially and economically 
important diseases including malaria (Plasmodium falciparum), African sleeping sickness 
(Trypanosoma brucei) and Chagas’ disease (Trypanosoma cruzi) 243,244, which are common 
in Africa and South America. Given the lack of vaccines, drug toxicity and the emergence of 
resistance, the development of new therapies for such parasitic diseases represents an area of  
urgent unmet need 95. Protozoan mitochondria are an attractive drug target because their 
mitochondria are not only essential for survival but are also quite different from those of their 
mammalian hosts 244 95 245. Therefore, although the application of mitochondria-based 
therapies in this setting is quite different to the indications discussed above, in that they do 
not target human mitochondria, given the significant unmet need and promising therapeutic 
potential, strategies targeted to plasmodium and trypanosome mitochondria will be discussed 
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below (FIG. 3). In addition, it should be noted that in contrast to the approaches discussed for 
other diseases, the potential therapeutic strategies outlined below aim to impair, rather than 
restore, mitochondrial function. 
Plasmodium falciparum, the protozoan that underlies malaria, infects 200 million 
people world-wide and kills some 0.4 million per year, but remains somewhat neglected by 
drug developers.  Plasmodium undergoes dramatic changes in mitochondrial metabolism and 
function depending on the stage in its life cycle and its host 244 95. Within the human red 
blood cell the protozoan contains a single, large mitochondrion, which is essential for 
survival 95. The P. falciparum mitochondrion contains a stripped-down respiratory chain 
comprising a non-proton pumping NADH dehydrogenase (ND2) that oxidises NADH in the 
cytosol, as well as conventional cytochrome bc1 and cytochrome oxidase complexes which 
contain subunits that are encoded by mtDNA 244. The bloodstream form of P. falciparum 
relies entirely on glycolysis for ATP production, but its mitochondrion nevertheless contains 
an active FoF1-ATP synthase that acts in reverse as a proton pump to help sustain a 
mitochondrial p that is essential for mitochondrial protein import and viability 95,244. The 
major role of the respiratory chain is to pass electrons from NADH to O2 to resupply NAD+ 
in order to sustain glycolysis 244. As P. falciparum lacks pyrimidine salvage pathways they 
rely on the mitochondrial enzyme  dihydroorotate dehydrogenase (DHODH) for pyrimidine 
biosynthesis 245 95,244. DHODH is thus itself a potential drug target.  Furthermore, as DHODH 
activity reduces CoQ to CoQH2  an active respiratory chain is also essential for pyrimidine 
biosynthesis by recycliing CoQH2 to CoQ 245 95,244.  
 The distinct and essential mitochondrial metabolism of P. falciparum immediately 
suggests that it should be a good drug target 95. This is illustrated by the malaria drug 
atovaquone, which inhibits the P. falciparum cytochrome bc1 complex more effectively than 
the mammalian complex 244. However, rapid resistance to atovoquone occurs because its 
binding site on the cytochrome bc1 complex is encoded by a gene on mtDNA which is more 
susceptible to oxidative damage and mutation, thereby  facilitating the evolution of resistance 
95,246. This has led to the search for other plasmodium selective cytochrome bc1 complex 
inhibitors and for ND2 inhibitors, with the latter less likely to generate resistance due to the 
nuclear location of its gene 246 95 95 244,246. The requirement for pyrimidine biosynthesis in 
plasmodium has also led to the development of DHOD inhibitors 245 246. One further 
interesting point to consider is that while the mode of action of the anti-plasmodium drug 
artemisinin is unclear, it may act by disrupting mitochondrial respiration 247.  
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 The Trypanosomatid protozoa that underlies African (sleeping sickness) and 
American (Chagas’ disease) tropanosomiasis are widespread in Africa and South America, 
but as with malaria these devastating diseases are relatively neglected by drug developers.  
The mitochondria of  Trypanosomatids are an attractive drug target, because they have 
different modes of metabolism, depending on host and stage of the life cycle, and are distinct 
from human mitochondria 243,248,249. The T. brucei trypomastigote stage in the blood stream of 
infected humans, which relies on glycolysis for ATP production, contains a single 
mitochondrion that has an unconventional respiratory chain that is essential for regenerating 
NAD+ from NADH to sustain glycolysis 249. NAD+ is regenerated from NADH by reduction 
of dihydroxyacetone phosphate to glycerol 3-phosphate by cytosolic glycerol 3-phosphate 
dehydrogenase 249.  The glycerol 3-phosphate is then reoxidised by mitochondrial glycerol 3-
phosphate dehydrogenase (mG3PDH), thereby reducing mitochondrial CoQ to CoQH2 which 
in turn is reoxidised by oxygen, catalysed by the alternative oxidase (AOX) in the 
mitochondrial respiratory chain 243,250. Trypansomatid mitochondria also contain an active 
FoF1-ATP synthase which acts in reverse as a proton pump to maintain the p that is essential 
to maintain mitochondrial protein import and biogenesis 251. The lack of AOX in humans 
makes it an appealing drug target 250 243, for example  the AOX inhibitor ascofuranone has 
been shown to be effective against T. brucei in mice in vivo 252.  
There are likely to be many other potential targets in protozoan mitochondria distinct 
from those in human mitochondria, for example some protozoans have unique metabolite 
transporters 108 and trypanosomatid mitochondria organise their mtDNA in concatenated 
chains, which makes them particularly sensitive to topoisomerase inhibitors 248.  
 
Challenges 
The development of mitochondrial therapies for common diseases faces considerable 
challenges. A key issue is the difficulty in assessing mitochondrial function and damage non-
invasively in patients 253. Currently, it can be difficult to know when to treat a patient with a 
mitochondrial therapy, or to determine whether the putative therapy acts on mitochondria or 
elsewhere 253. There is an urgent need for biomarkers that are  specific, sensitive over short 
periods of time and clinically meaningful 253.  
 To assess mitochondrial function, the most direct approach is to isolate mitochondria 
and assess their activity ex vivo, for example as is done in muscle biopsies in the assessment 
of mitochondrial disease patients. However, this is too invasive for repeated use and hence 
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there has been considerable effort devoted to assessing mitochondrial activity in blood 
leukocytes and platelets 254-256. In these approaches, the full  range of assessments of 
mitochondrial function or damage could be applied 254, but often now the approach is to 
subject the cells to bioenergetic profiling by respirometry to infer mitochondrial function 257 
254,255.  This could in principle be applied directly to the assessment of mitochondrial function 
in these cell types, but more usually the analysis of mitochondrial function in the blood is 
used as a surrogate marker for changes in mitochondrial activity in other, less accessible 
tissues, or as an indicator that a drug designed to affect mitochondria is effective in patients. 
These approaches are a current area of considerable interest, with the hope that measurements 
of mitochondrial function in the blood can be used to infer mitochondrial function and drug 
impact in other tissues.  
  Overall mitochondrial function in the whole body can be assessed by changes in the 
blood or urine of the lactate/pyruvate ratio 258, and occasionally of changes of other 
metabolites, or by measuring markers of oxidative damage such as F2-isoprostanes 259. This 
can be extended to link particular metabolic signatures in plasma and urine, which shows 
promise in some situations 260. We may also be able to assess mitochondrial stress responses, 
such as changes in one carbon metabolism that affect the release of fibroblast growth factor 
21 (FGF21) or growth differentiation factor 15 (GDF 15) into the circulation 6. Other 
possibilities are the measurement of the release of mtDNA or mitochondrial derived 
exosomes and microvesicles into the circulation 261. However, a generic problem with these 
approaches is the difficulty of inferring the site of the tissue damage that led to release of the 
damage markers into the circulation. The ability to assess mitochondrial function in vivo has 
been approached in animals by targeting molecules to mitochondria to generate exomarkers 
262,263, but as this requires the isolation of the tissue its application to patients is currently 
limited to biopsy material 264.  
 Imaging technologies can be used to infer mitochondrial function within the tissues of 
interest in vivo. 31P-magnetic resonance spectroscopy (MRS) reports on ATP and creatine 
phosphate levels, which can be used to assess mitochondrial dysfunction in muscles and the 
brain 265 266. Related to this, is the endogenous assessment of mitochondrial oxygen 
consumption which can be done in vivo with near infrared spectroscopy measurements 267. 
Alternatively, mitochondrial function can be assessed by administering compounds to the 
patient and visualising their distribution and metabolism. For example, positron emission 
tomography (PET) can be used to follow changes in mitochondrial   in vivo by injecting a  
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TPP cation tagged with a PET-visible atom 268. Alternatively, the transformations of 13C-
labelled metabolites can be assessed in vivo using magnetic resonance spectroscopy (MRS) 
266, and the sensitivity can be greatly enhanced by hyperpolarization of the 13C-labelled 
metabolites prior to infusion 269.  The development of these and related approaches to assess 
mitochondrial function in vivo is central to the development of mitochondrial pharmacology.  
Another major challenge in targeting drugs to mitochondria is how to achieve tissue 
selectivity, so that the drug is only delivered to mitochondria in the tissue or cell type of 
interest, minimising off-target effects. This can be addressed by the tissue-selective activation 
of a drug, as was done for DNP 176. A related goal is to activate drugs only within 
mitochondria, or to confine them there in order to minimise side effects 42. These concerns 
are particularly acute when the intention is to kill cells such as protozoal parasites. There are 
a number of chemical biology approaches that suggest pathways towards these goals, such as 
selective activation of pro-drugs by enzymes, co-administration of multiple mitochondria-
targeted compounds that react together within the organelle 270, or combination with other 
factors such as light or radiotherapy 271.  
An appealing opportunity is raised by the repeated finding that mitochondria 
contribute to pathology by elevated ROS production, oxidative damage, carbon stress, 
disruption to calcium homeostasis, induction of the MPTP, the accumulation of protein 
aggregates and elevated inflammation. This suggests that a similar pattern of mitochondrial 
damage underlies disparate pathologies, enabling “mitochondrial” drugs to be applied to 
many pathologies. A particularly intriguing corollary is that these same hallmarks of 
mitochondrial dysfunction are also found in organismic ageing and cell senescence 272. This 
raises the possibility that mitochondrial drugs may increase overall healthspan. For example, 
the National Institute on Aging (NIA) intervention testing programme (ITP) 273 showed that 
metformin in conjunction with rapamycin increased healthy lifespan 274 275, and now other 
mitochondrial drugs such as MitoQ are being assessed in the NIA-ITP 
(https://www.nia.nih.gov/research/dab/interventions-testing-program-itp). It will be 
interesting to see how these interventions affect “normal” aging and healthspan, raising the 
possibility of extending any promising findings with mitochondrial therapies in animals to 
prophlyactic treatments to enhance the wellbeing of  our aging populations  276.  
 
Outlook 
Mitochondrial dysfunction can contribute to the pathology of many “common” disorders and 
discussed general strategies by which small molecule therapies targeting mitochondria may 
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be used to treat these “secondary” mitochondrial diseases are emerging. This raises the 
prospect of treating common pathologies of considerable social, medical, and economic 
importance with novel mitochondria-targeted therapies. 
Of course, we have only considered a small number of the many possible diseases and 
indications for which mitochondrial therapies may be useful. For example, a major issue with 
many drugs is mitochondrial toxicity, which leads to the hepatotoxicity of acetaminophen 277, 
the heart damage caused by some cancer drugs 278 and the damage associated with 
antiretroviral therapies 74. Co-administration of compounds designed to protect mitochondria 
may enable the wider use of drugs that are currently too toxic for routine use 279. As well as 
the many common disorders discussed throughout this review which have a relatively clear 
“physical” aetiology, a further intriguing possibility is that mitochondrial dysfunction may 
also contribute to psychological and psychiatric disorders such as anxiety and depression  
280,281. How mitochondrial dysfunction can impact on mental processes is obscure at present, 
but raises the prospect that intervening at the mitochondrial level may impact psychological 
and psychiatric disorders 280,281. Time will tell whether focussing on mitochondria will 
provide new approaches to treat these and other common pathologies beyond the scope of 
this review.  
In conclusion, we have shown how we can think anew about therapies for common 
pathologies. Our view is that focussing on mitochondria and developing the field of 
mitochondrial pharmacology offers hope for new therapies in many of the most important 
pathologies facing humanity.  
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Figure legends 
 
Figure 1 How mitochondria contribute to common pathologies 
The key roles of mitochondria are illustrated here and discussed further in Box 1. Disruption 
to mitochondrial function can lead to pathology by affecting several pathways: ATP supply; 
mitochondrial biogenesis; mitochondrial fission/fusion and organelle quality control; ROS 
production; induction of the mitochondrial permeability transition pore (MPTP); release of 
pro-apoptotic factors to the cytosol by induction of mitochondrial outer membrane 
permeabilisation (MOMP); activation of the innate immune system by release of damage 
associated molecular patterns (DAMPs); mitochondrial signaling; calcium homeostasis. 
VDAC, voltage dependent ion channel. TOM, translocase of the outer membrane; TIM, 
translocase of the inner membrane. CAC, citric acid cycle; Q, Coenzyme Q; p, 
protonmotive force; , membrane potential; ETF, electron transfer flavoprotein; CaU; 
calcium uniporter.  
 
Figure 2 Mitochondria as a therapeutic target in ischemia-reperfusion injury 
Ischemia arises when blood flow to an organ is restricted. This causes the accumulation of 
metabolites such as lactate, succinate and depletion of ATP as well as disruption to calcium 
homeostasis. When blood flow is restored there is rapid oxidation of the accumulated 
succinate that drives ROS production at complex I by RET. This induces oxidative damage 
and in conjunction with an accumulation of calcium leads to induction of the MPTP resulting 
in cell death. This model of IR injury applies to IR injury in many contexts and leads to tissue 
damage and opens up rational mitochondrial interventions. Potential therapeutic strategies 
include preventing the accumulation of succinate (i), preventing the oxidation of succinate 
upon reperfusion (ii), preventing the ROS production by complex I (iii), blocking the 
downstream effects of ROS (iv), or preventing induction of the MPTP (v). In addition, the 
release of succinate and mitochondrial DAMPs into the circulation act as proinflammatory 
signals that will contribute to tissue damage following IR injury.  MPTP, mitochondrial 
permeability transition pore; SDH, succinate dehydrogenase; DAMP, damage-associated 
molecular patterns. 
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Figure 3 Mitochondria as a therapeutic target in protozoal infections 
The protozoan Plasmodium falciparum causes malaria while the trypansomatids 
Trypanosoma brucei and Trypanosoma cruzi underlie sleeping sickness and Chagas’ disease, 
respectively. Several aspects of the metabolism of plasmodium and trypansomatid 
mitochondria are quite distinct from those in mammalian mitochondria, providing attractive 
druggable targets to treat protozoal infections. AOX, alternative oxidase; mG3PDH, 
mitochondrial glycerol 3 phosphate dehydrogenase.  
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Boxes 
 
 
Box 1   Mitochondrial biogenesis, oxidative phosphorylation and metabolism 
Mitochondria are assembled through the interplay between the nuclear and mitochondrial 
genomes. Mammalian mtDNA encodes 37 genes, 13 for polypeptide components of the 
oxidative phosphorylation machinery, as well as the 22 tRNAs and 2 rRNAs required for 
their transcription and translation within the organelle 6. Mitochondria contain around 1,500 
types of protein that are encoded on the nuclear genome, translated on cytoplasmic ribosomes 
and are then imported into mitochondria by the Translocase of the Outer Membrane (TOM) 
and the Translocase of the Inner Membrane (TIM) complexes. Phospholipids are either 
synthesised in the organelle or imported after synthesis in the endoplasmic reticulum 
membrane. The mitochondrial outer membrane is similar in composition to those in the rest 
of the cell and contains a pore formed by the -barrel protein voltage dependent ion channel 
(VDAC) that enables interchange between the intermembrane space and the cytosol. The 
inner membrane contains a large amount of the phospholipid cardiolipin and its area is 
greatly enhanced by infolding into cristae that are in the shape of a flattened disc-like sac 
with a narrow neck that connects it to the intermembrane space. The flattened shape is 
maintained by a line of FoF1-ATP synthase dimers while the neck structure and contact sites 
between the inner and outer membranes are maintained by the mitochondrial contact site and 
cristae organizing system (MICOS). The extensive surface area of the cristae is required for 
effective oxidative phosphorylation. The rest of the inner membrane is called the boundary 
membrane and is the location of mitochondrial protein import.  
 Mitochondria are not isolated organelles, but are a dynamic network within the cell, 
continually fusing and dividing. Mitochondrial fusion is determined by proteins such as 
mitofusins (MFN 1 & 2) and (Optic Atrophy 1 (OPA1), while fission is controlled by 
proteins such as Dynamin Related Protein 1 (DRP1). Mitochondrial morphology is a balance 
between fusion and fission events, the latter being associated with contact sites to the 
endoplasmic reticulum, and are intimately linked to mitochondria quality control and the 
degradation of damaged mitochondria through mitophagy 15. In addition, there are a number 
of proteases, lipases and nucleases that act within the organelle, to degrade or repair 
internally damaged parts of the organelle. Mitochondria can also package and bud off 
damaged material as mitochondria-derived vesicles.  
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The mitochondrial content of the cell is set by the balance of mitochondrial biogenesis 
and degradation, which requires the regulation of the expression of the nuclear and 
mitochondrial genomes in response to the cell’s metabolic and energy demands. These 
processes are regulated by a range of transcription factors, such as Nuclear Respiratory 
Factors (NRF) 1 and NRF2, in association with transcriptional coactivators such as 
peroxisome proliferator-activated receptor-γ coactivator-1α (PGC1-) 75. The activity of 
these factors themselves are frequently modified by posttranslational modification, for 
example by the energy sensor adenosine monophosphate activated kinase (AMPK) which 
upon activation by a lowered ATP/ADP or ATP/AMP ratio inhibits anabolic pathways and 
stimulates catabolic pathways 13. Together these regulatory pathways enable mitochondrial 
function to adapt to both the long and short-term requirements of the cell. 
 Energy metabolism is the core function of mitochondria. At its heart is the citric acid 
cycle (CAC) that takes the acetyl-CoA generated from the pyruvate provided by glycolysis 
and breaks the acetyl moiety down to CO2, with the electrons going to NADH in the matrix 
or to the CoenzymeQ (CoQ) pool within the mitochondrial inner membrane (FIG. 1). Fatty 
acids are also broken down by -oxidation to acetyl-CoA with the electrons passed on to 
NADH or the CoQ pool. NADH transfers its electrons through complex I to the CoQ pool, 
which also receives electrons from many other sources. From the CoQ pool, the electrons 
pass through complex III to cytochrome c, before reducing oxygen to water at complex IV. 
The reduction potential difference driving electron movement through complexes I, III and 
IV is used to pump protons across the mitochondrial inner membrane which builds up a 
protonmotive force (p) across the mitochondrial inner membrane comprising a membrane 
potential () of ~150- 160 mV and a pH gradient of ~ 0.5 pH units, which is then used to 
drive ATP synthesis at the FoF1-ATP synthase 282. The ATP is exported from the matrix to 
the cytosol in exchange for ADP by the adenine nucleotide exchanger (ANT) while the Pi is 
symported with H+, and so mitochondrial ATP synthesis can drive ATP-dependent work in 
the cytosol 108.  
In addition to energy metabolism, mitochondria are also central to many other 
metabolic pathways, synthesising iron sulfur (FeS) centers, heme and CoQ while the CAC is 
intimately involved in cellular amino acid and carbohydrate metabolism. These core 
metabolic roles require the continual and selective transport of polar metabolites between the 
mitochondria and the cytoplasm, without proton permeation of the inner membrane which 
would uncouple ATP synthesis 108. Metabolite transport occurs through families of solute 
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carriers in the inner membrane (e.g. the SLC25 family 108) while VDAC enables transport of 
a range of metabolites across the mitochondrial outer membrane.  
 
 
Box 2   Targeting small molecules to mitochondria.  
 
The ability to selectively target compounds to mitochondria is an important development in 
designing drugs to impact on mitochondria and thereby treat common pathologies. 
Mitochondria-targeting of drugs can enhance potency, avoid side effects and speed up 
delivery. There are a number of approaches to target small molecules to mitochondria. One 
widely used approach is to utilise the mitochondrial membrane potential () which drives 
the accumulation of lipophilic cations within mitochondria 14,41. Lipophilic cations, notably 
the triphenylphosphonium (TPP) cation but many others can be used, have the property of 
being able to pass through biological phospholipid bilayers, due to a lowering of the 
activation energy for movement through the bilayer. This arises due to distribution of the 
charge across a large hydrophobic surface area, either by shielding the charge in the case of 
TPP or by charge delocalisation in the case of planar conjugated aromatic systems such as 
rhodamine. The Nernst equation indicates that for every ~60 mV increase in  the 
concentration of these compounds increases 10-fold, hence the compounds first concentrate 
in the cytosol 5- 10 fold in response to the plasma membrane potential (plasma) of -30 to -60 
mV and then further concentrate 100 – 500 fold within the mitochondrial matrix in response 
to the mitochondrial  of -140 – -160 mV. Thus, lipophilic compounds can be concentrated 
several thousand-fold within the mitochondrial matrix. By conjugation to a TPP,  bioactive 
molecules  can be delivered to the matrix in vivo provided they  are not too polar. 
Importantly, these can be delivered orally, or IV and are rapidly taken up in to many organs 
in vivo 283 and have been shown to be safe long term in human trials 22,23. A number of 
different peptides can be used to target compounds to mitochondria 20,42,284,285 286. These 
peptides all contain positive charges and uptake is assumed to be driven by the mitochondrial 
membrane potential , although the mechanism has been less investigated than for 
lipophilic cations. 
 
Box 3   Mitochondria in cancer therapies  
 
It is now clear that many cancer cells reprogram their metabolism and mitochondrial function 
to provide the building blocks to generate lipids, proteins and nucleic acids, and to sustain 
 52 
mitotic signals to enable cell proliferation 287 288 289. Consequently, changes in mitochondrial 
metabolism and redox status are now considered hallmarks of cancer 287 288,290. The metabolic 
reprogramming of mitochondria in cancer was first noted by Warburg, who found that cancer 
cells converted large amounts of glucose to lactate even in the presence of oxygen, a 
phenomenon that was later defined as aerobic glycolysis 291,292. Initially, it was thought this 
metabolic feature of cancer arose from mitochondrial dysfunction or damage, however it is 
now clear that aerobic glycolysis is an inherent property of cancer and that functional 
mitochondria are essential for cancer cells to proliferate 293 287,294. A further property of many 
cancer cells is enhanced mitochondrial ROS production and a redox imbalance that is thought 
to stimulate cell proliferation and inhibit growth suppression 295 287,296. While this summary is 
inevitably an oversimplification, it shows why targeting mitochondrial metabolism is a 
promising approach to kill cancer cells 287 290,297.  
A further aspect of mitochondria in most cancer cells is their higher p than in non-
transformed cells 298-302. One factor contributing to this may be that the high flux of ATP 
production by glycolysis decreases p utilisation for ATP synthesis by oxidative 
phosphorylation 293 287,294. Irrespective of the underpinning reasons, the elevated 
mitochondrial p in cancer cells, usually manifesting as an elevated , is a well-established 
attribute of many cancer cells 303-305 and can be used to selectively enhance drug uptake into 
the mitochondria of cancer cells compared to untransformed cells 302 303-305.  
Many of these properties of mitochondria in cancer cells can be used to enhance cell 
killing. For example, oxidative phosphorylation is required for cancer cell survival and 
growth 293 287,294,306, hence selectively disrupting this process in tumour mitochondria without 
overt toxicity to other cells is an appealing therapeutic possibility.  Although there are 
considerable uncertainties and variations, many cancer cells seem to have enhanced 
mitochondrial ROS production which is thought to  act as a mitogenic signal 307 308 287,309 296 
295,310. This putative enhancement of mitochondrial ROS production reveals two therapeutic 
strategies 307. The first is to disrupt mitogenic ROS signaling from mitochondria, as has been 
shown in animal models using mitochondria-targeted antioxidants to inhibit cell proliferation 
and metastasis 295 287,311. The other therapeutic strategy utilizes the fact that cancer cells often 
upregulate their antioxidant defences, possibly to cope with the higher levels of redox stress 
associated with mitochondrial mitotic signals 287 296. The greater oxidative stress in some 
cancer cells makes them more susceptible to disrupting mitochondrial antioxidant defences 
than non-transformed cells 296,310 312. Many cancer cells evade death due to defective 
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induction of the mitochondrial apoptotic pathway, for example due to overexpression of the 
anti-apoptotic protein B-cell lymphoma 2 (Bcl-2) 96 313. The point of no-return for 
mitochondrial apoptosis is induction of mitochondrial outer membrane permeabilisation 
(MOMP) and the subsequent release of pro-apoptotic factors such as cytochrome c into the 
cytosol 314,315. Pro-apoptotic proteins,  such as Bcl-2-associated X (BAX) and Bcl-2 
homologous antagonist/killer (BAK) form the MOMP pore and these proteins are normally 
held in check by anti-apoptotic proteins of the Bcl-2 family 314,315. The balance between these 
anti- and pro-apoptotic proteins is determined  by the BH3-only pro-apoptotic proteins,  such 
as truncated Bid (tBid), which bind to anti-apoptotic members of the Bcl-2 family leading to 
MOMP 316. Thus,  BH3 mimetic drugs such as venetoclax, have been developed to counteract 
the suppression of apoptosis in cancer cells by excess Bcl-2 anti-apoptotic members, and 
thereby use mitochondria to kill cancer cells 313,315 309 96. 
In summary, the role of mitochondria in several facets of cancer progression, coupled 
with the possibility of enhanced selectivity in targeting mitochondria within cancer cells, 
suggests multiple novel therapeutic approaches.  
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Glossary 
 
ROS 
Reactive oxygen species such as superoxide and hydrogen peroxide are produced as a 
byproduct of normal metabolism. They can cause non-specific oxidative damage to proteins, 
DNA and lipids that contributes to pathologies  and  can also act as redox signals.  
 
RET 
Complex I in the mitochondrial respiratory chain can produce superoxide by reverse electron 
transport (RET). This occurs when the p is high and  the CoQ pool is reduced, causing 
electrons to flow backwards through complex I.  
 
CAC 
The citric acid cycle takes acetyl CoA generated from the pyruvate produced by glycolysis to 
fuse with oxaloacetate to form  citrate.  The citrate is then broken down to release CO2 while 
providing electrons to the respiratory chain and regenerating oxaloacetate to keep the CAC 
turning.  
 
MPTP 
The mitochondrial permeability transition pore is a large conductance pore that opens in the 
mitochondrial inner membrane in response to oxidative stress and elevated calcium levels. 
This leads to mitochondrial swelling and cell death. 
 
Protonmotive force 
The mitochondrial respiratory chain passes electrons from NADH or flavins on to oxygen 
and in doing so pumps protons across the mitochondrial inner membrane thereby establishing 
a promotive force (p). The p is comprised of a mitochondrial membrane potential () of 
about 150 mV  and a pH gradient of about 0.5 pH units.  
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